

Rabbit Anti-VEGFR2 antibody

SL0565R

Product Name:	VEGFR2
Chinese Name:	血管内皮生长因子受体2抗体
Alias:	VEGF Receptor 2; CD309; CD309 antigen; Fetal liver kinase 1; FLK-1; FLK1; KDR; Kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein tyrosine kinase receptor FLK1; Protein-tyrosine kinase receptor flk-1; Tyrosine kinase growth factor receptor; Vascular endothelial growth factor receptor 2; VEGFR 2; VEGFR; VEGFR-2; VEGFR2; VGFR2 HUMAN.
文献引用	Specific References(6) SL0565R has been referenced in 6 publications.
	[IF=4.15]Wang, Nan, et al. "Vascular endothelial growth factor stimulates endothelial
	differentiation from mesenchymal stem cells via Rho/myocardin-related transcription
	factor-A signaling pathway." The International Journal of Biochemistry & Cell Biology
	(2013).WB;Human, Rat.
	PubMed:23624342
	[IF=3.73]Gao, Jin-Hang, et al. "Celecoxib Ameliorates Portal Hypertension of the
	Cirrhotic Rats through the Dual Inhibitory Effects on the Intrahepatic Fibrosis and
Publiced	Cirrhotic Rats through the Dual Inhibitory Effects on the Intrahepatic Fibrosis and Angiogenesis." PLOS ONE 8.7 (2013): e69309. WB, IHC-P;Rat .
Pub Med	
Pub Med	Angiogenesis." PLOS ONE 8.7 (2013): e69309.WB, IHC-P;Rat.
Pub Med	Angiogenesis." PLOS ONE 8.7 (2013): e69309. WB, IHC-P;Rat . <u>PubMed:23922700</u>
Pub Med	Angiogenesis." PLOS ONE 8.7 (2013): e69309. WB, IHC-P;Rat . PubMed:23922700 [IF=2.02]Wang, Zheng, et al. "RhGH attenuates ischemia injury of intrahepatic bile
Pub Med	Angiogenesis." PLOS ONE 8.7 (2013): e69309. WB, IHC-P;Rat . PubMed:23922700 [IF=2.02]Wang, Zheng, et al. "RhGH attenuates ischemia injury of intrahepatic bile ducts relating to liver transplantation." Journal of Surgical Research 171.1 (2011): 300-
Pub Med	Angiogenesis." PLOS ONE 8.7 (2013): e69309. WB, IHC-P;Rat . PubMed:23922700 [IF=2.02]Wang, Zheng, et al. "RhGH attenuates ischemia injury of intrahepatic bile ducts relating to liver transplantation." Journal of Surgical Research 171.1 (2011): 300-310.IHC-P;Rat.

	Medicine & Biology (2014)IHC-P;Mouse.
	PubMed:24613557
	[IF=3.17]Li, Junqin, et al. "Fatty Acid Synthase Mediates the Epithelial-Mesenchymal
	Transition of Breast Cancer Cells." International Journal of Biological Sciences 10.2
	(2014): 171-180. WB;Human .
	<u>PubMed:24520215</u>
	[IF=1.07] Yang, Lei, et al. "Promotive effect of salvia extract on angiogenesis of
	myocardium in rats with myocardial infarction." Int J Clin Exp Med 10.6 (2017): 9245-
	9251.IHC-F;Rat.
	PubMed:0
Organism Species:	Rabbit
Clonality:	Polyclonal
React Species:	Human, Mouse, Rat, Dog, Pig, Cow,
	WB=1:500-2000ELISA=1:500-1000IHC-P=1:400-800Flow-Cyt=1µg/Test(Paraffin
Annlications	sections need antigen repair)
Applications:	not yet tested in other applications.
	optimal dilutions/concentrations should be determined by the end user.
Molecular weight:	147kDa
Cellular localization:	The nucleuscytoplasmicThe cell membraneSecretory protein
Form:	Lyophilized or Liquid
Concentration:	lmg/ml
immunogen:	KLH conjugated synthetic peptide derived from human VEGFR2:1001-1100/1356 <cytoplasmic></cytoplasmic>
Lsotype:	IgG
Purification:	affinity purified by Protein A
Storage Buffer:	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized
Storogo	antibody is stable at room temperature for at least one month and for greater than a year
Storage:	when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of
	antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMed:	<u>PubMed</u>
	Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial
	cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as
	kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the
	main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular
Product Detail:	morphogenesis and sprouting. The signalling and trafficking of this receptor are
- I Junet Detuiii	regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor,
	integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc Mutations of this gene
	are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009].
	Function:
	I uncuon.

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA-and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1.4.5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

Subunit:

Interacts with MYOF. Interacts with VEGFA, VEGFC and VEGFD. Monomer in the absence of bound VEGFA, VEGFC or VEGFD. Homodimer in the presence of bound dimeric VEGFA, VEGFC or VEGFD. Can also form heterodimers with FLT1 and FLT4. Interacts (tyrosine phosphorylated) with FYN, NCK1, PLCG1 and SHB. Interacts with HIV-1 Tat. Interacts with CBL. Interacts with SH2D2A/TSAD and GRB2.

Subcellular Location:

Isoform 1: Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early endosome. Note=Detected on caveolae-enriched lipid rafts at the cell surface. Is recycled from the plasma membrane to endosomes and back again. Phosphorylation triggered by VEGFA binding promotes internalization and subsequent degradation. VEGFA binding triggers internalization and translocation to the nucleus. Isoform 2: Secreted (Probable).

Isoform 3: Secreted.

Tissue Specificity:

Detected in cornea (at protein level). Widely expressed.

Post-translational modifications:

N-glycosylated.

Ubiquitinated. Tyrosine phosphorylation of the receptor promotes its polyubiquitination, leading to its degradation via the proteasome or lysosomal proteases. Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-951 is important for interaction with

SH2D2A/TSAD and VEGFA-mediated reorganization of the actin cytoskeleton. Phosphorylation at Tyr-1175 is important for interaction with PLCG1 and SHB. Phosphorylation at Tyr-1214 is important for interaction with NCK1 and FYN. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.

DISEASE:

Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. Note=Plays a major role in tumor angiogenesis. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Similarity:

Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.

Contains 7 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 protein kinase domain.

SWISS:

P35968

Gene ID:

3791

Database links:

Entrez Gene: 3791Human

Entrez Gene: 407170Cow

Entrez Gene: 482154Dog

Entrez Gene: 16542Mouse

Entrez Gene: 25589Rat

Omim: 191306Human

SwissProt: P35968Human


SwissProt: P35918Mouse

Important Note:

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

The cell membrane受体(Membrane Receptors) 成血细胞Maker

VEGFR-2是一种The cell membrane受体激酶,对血管内皮生长因子-VEGF有高度的亲和性,主要功能是参与vascular endothelial cell生长和血管生成的调控,参与vascular endothelial cell的生长。用于各种恶性Tumour的研究。



Picture:

Sample:


Skin(Mouse) Lysate at 40 ug

Primary: Anti-VEGFR2 (SL0565R) at 1/300 dilution

Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution

Predicted band size: 147 kD

Observed band size: 147kD



Sample:


Embryon (Mouse)Lysate at 40 ug

Primary: Anti-VEGFR2 (SL0565R) at 1/300 dilution

Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution


Predicted band size: 147 kD

Observed band size: 147kD



Tissue/cell: Rat liver; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37°C for 20 min;


Incubation: Anti-VEGFR2/FLK1 Polyclonal , Unconjugated(SL0565R) 1:100, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining



Tissue/cell: human lung carcinoma;4% Paraformaldehyde-fixed and paraffinembedded;

Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min;


Incubation: Anti-VEGFR2 Polyclonal Antibody, FITC conjugated (SL0565R), at 1:200 dilution for 40 minutes at 37°C. DAPI(5ug/ml,blue,C-0033) was used to stain the cell nuclei



Tissue/cell: human lung carcinoma;4% Paraformaldehyde-fixed and paraffinembedded;

Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min;

Incubation: Anti-VEGFR2 Polyclonal Antibody, PE conjugated (SL0565R), at 1:200 dilution for 40 minutes at 37°C. DAPI(5ug/ml,blue,C-0033) was used to stain the cell nuclei



Tissue/cell: Human esophageal cancer tissue;4% Paraformaldehyde-fixed and paraffin-embedded;

Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Incubation: Anti-VEGFR2 Polyclonal Antibody, Unconjugated(SL0565R) 1:200,

overnight at 4°C; The secondary antibody was Goat Anti-Rabbit IgG, Cy3 conjugated (SL0565R)used at 1:200 dilution for 40 minutes at 37°C.

DAPI(5ug/ml,blue,C-0033) was used to stain the cell nuclei